Search

Author/Creator Goy, Andre

21. Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. (24th April 2015)

Authors:
Howlett, Christina; Snedecor, Sonya J.; Landsburg, Daniel J.; Svoboda, Jakub; Chong, Elise A.; Schuster, Stephen J.; Nasta, Sunita Dwivedy; Feldman, Tatyana; Rago, Allison; Walsh, Kristy M.; Weber, Scott; Goy, Andre; Mato, Anthony
Journal:
British journal of haematology
Issue:
Volume 170:Number 4(2015:Aug.)
Page Start:
504
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Issue 2 (February 2016)

Authors:
Chanan-Khan, Asher; Cramer, Paula; Demirkan, Fatih; Fraser, Graeme; Silva, Rodrigo Santucci; Grosicki, Sebastian; Pristupa, Aleksander; Janssens, Ann; Mayer, Jiri; Bartlett, Nancy L; Dilhuydy, Marie-Sarah; Pylypenko, Halyna; Loscertales, Javier; Avigdor, Abraham; Rule, Simon; Villa, Diego; Samoil...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 2(2016:Feb.)
Page Start:
200
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

23. Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study. Issue 9 (2nd September 2018)

Authors:
Cramer, Paula; Fraser, Graeme; Santucci-Silva, Rodrigo; Grosicki, Sebastian; Dilhuydy, Marie-Sarah; Janssens, Ann; Loscertales, Javier; Rule, Simon; Goy, Andre; Traina, Shana; Chan, Eric K. H.; Diels, Joris; Sengupta, Nishan; Mahler, Michelle; Salman, Mariya; Howes, Angela; Chanan-Khan, Asher
Journal:
Leukemia & lymphoma
Issue:
Volume 59:Issue 9(2018)
Page Start:
2075
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

24. Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the Pandemic. (19th February 2022)

Authors:
Lai, Catherine; Potosky, Arnold L.; McGuire, Colleen; Lobo, Tania; Ahn, Jaeil; Haddad, Bassem R.; Richards, Ernest W.; Anand, Palka; Wright, Kristen; Christenson, Robert H.; Boyle, Lisa; Goy, Andre; Atkins, Michael B.
Other Names:
Qian Liren Academic Editor.
Journal:
Journal of oncology
Issue:
Volume 2022(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

25. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐Hodgkin lymphomas. (27th June 2013)

Authors:
Hagemeister, Fredrick; Rodriguez, Maria Alma; Deitcher, Steven R.; Younes, Anas; Fayad, Luis; Goy, Andre; Dang, Nam H.; Forman, Arthur; McLaughlin, Peter; Medeiros, Leonard Jeffrey; Pro, Barbara; Romaguera, Jorge; Samaniego, Felipe; Silverman, Jeffrey A.; Sarris, Andreas; Cabanillas, Fernando
Journal:
British journal of haematology
Issue:
Volume 162:Number 5(2013:Sep.)
Page Start:
631
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

26. Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. Issue 5 (13th May 2022)

Authors:
Dreyling, Martin; Goy, Andre; Hess, Georg; Kahl, Brad S.; Hernández-Rivas, José-Ángel; Schuier, Natasha; Qi, Keqin; Deshpande, Sanjay; Zhu, Angeline; Parisi, Lori; Wang, Michael L.
Journal:
HemaSphere
Issue:
Volume 6:Issue 5(2022)
Page Start:
e712
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

27. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Issue 1 (January 2019)

Authors:
Locke, Frederick L; Ghobadi, Armin; Jacobson, Caron A; Miklos, David B; Lekakis, Lazaros J; Oluwole, Olalekan O; Lin, Yi; Braunschweig, Ira; Hill, Brian T; Timmerman, John M; Deol, Abhinav; Reagan, Patrick M; Stiff, Patrick; Flinn, Ian W; Farooq, Umar; Goy, Andre; McSweeney, Peter A; Munoz, Javie...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 1(2019)
Page Start:
31
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

28. Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial. (28th April 2015)

Authors:
Goy, Andre; Kalayoglu Besisik, Sevgi; Drach, Johannes; Ramchandren, Radhakrishnan; Robertson, Michael J.; Avivi, Irit; Rowe, Jacob M.; Herbrecht, Raoul; Van Hoof, Achiel; Zhang, Lei; Cicero, Sherri; Fu, Tommy; Witzig, Thomas
Journal:
British journal of haematology
Issue:
Volume 170:Number 4(2015:Aug.)
Page Start:
496
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

29. Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma. Issue 10 (28th August 2017)

Authors:
Witzig, Thomas E.; Luigi Zinzani, Pier; Habermann, Thomas M.; Tuscano, Joseph M.; Drach, Johannes; Ramchandren, Radhakrishnan; Kalayoglu Besisik, Sevgi; Takeshita, Kenichi; Casadebaig Bravo, Marie‐Laure; Zhang, Lei; Fu, Tommy; Goy, Andre
Journal:
American journal of hematology
Issue:
Volume 92:Issue 10(2017:Oct.)
Page Start:
E575
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗